Company intelligence / Profile preview

HSK GeneTech

Chengdu, Sichuan, Chinahaisco.com ↗

Ownership: Private
Development stage: Other

Overview

HSK GeneTech is a clinical-stage biotechnology company specializing in the development of adeno-associated virus (AAV) mediated gene therapies for rare genetic disorders. As a subsidiary of Sichuan Haisco Pharmaceutical Group, the company leverages a proprietary AAV platform to design and manufacture high-potency genetic medicines. Their lead candidate, HSK34890, is currently undergoing clinical evaluation for the treatment of Hemophilia B, aiming to provide a durable therapeutic effect through a single administration. The company's pipeline also includes programs for Hemophilia A and other metabolic diseases. HSK GeneTech is committed to establishing a full-value chain capability in gene therapy, from early-stage discovery to GMP-compliant manufacturing.

Therapeutic areas: Hematology
Modalities: Gene therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on HSK GeneTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSK GeneTech.